Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: What We Already Know

Adham E Obeidat; Ratib Mahfouz; Gabriel Monti; Landon Kozai; Mohammad Darweesh; Mahmoud M Mansour; Ahmad Alqam; David Hernandez

doi:10.7759/cureus.21773

Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: What We Already Know

Cureus. 2022 Jan 31;14(1):e21773. doi: 10.7759/cureus.21773. eCollection 2022 Jan.

Authors

Adham E Obeidat¹, Ratib Mahfouz², Gabriel Monti³, Landon Kozai¹, Mohammad Darweesh⁴, Mahmoud M Mansour⁵, Ahmad Alqam⁶, David Hernandez⁷

Affiliations

¹ Internal Medicine, University of Hawaii, Honolulu, USA.
² Internal Medicine, Kent Hospital, Warwick, USA.
³ Internal Medicine, Oregon Health & Science University, Portland, USA.
⁴ Internal Medicine, East Tennessee State University, Johnson City, USA.
⁵ Internal Medicine, University of Missouri School of Medicine, Columbia, USA.
⁶ Internal Medicine, Englewood hospital, Englewood, USA.
⁷ Internal Medicine, Brown University, Providence, USA.

Abstract

Acute pancreatitis is the most common serious complication of endoscopic retrograde cholangiopancreatography (ERCP) resulting in significant morbidity and occasional mortality. Post-ERCP pancreatitis (PEP) has been recognized since ERCP was first performed, and many studies have shown a consistent risk that must be balanced against the many benefits of this procedure. This review will discuss the pathogenesis, epidemiology, potential risk factors, and clinical presentation of PEP. Moreover, it will discuss in detail the most recent updates of PEP prevention and management.

Keywords: abdominal pain; acute pancreatitis; amylase; ercp; lipase.

Publication types

Review